Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ciprofloxacin in preparation of human cytomegalovirus inhibitor

A technology of human cytomegalovirus and ciprofloxacin, which is applied in the directions of antiviral agents, medical preparations containing active ingredients, organic active ingredients, etc., to achieve the effect of preventing and/or treating diseases

Active Publication Date: 2020-10-30
CANVEST WUHAN BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In recent years, research on anti-HCMV drugs has made some progress, mainly based on broad-spectrum antiviral drugs such as ganciclovir, interferon therapy, and symptomatic treatment; A new type of HCMV inhibitor has also shown good antiviral activity in vivo and in vitro tests, but clinical drug-resistant virus strains are also increasing, and there is still an urgent need to develop specific therapeutic drugs against HCMV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ciprofloxacin in preparation of human cytomegalovirus inhibitor
  • Application of ciprofloxacin in preparation of human cytomegalovirus inhibitor
  • Application of ciprofloxacin in preparation of human cytomegalovirus inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] In this example, after HCMV infects trophoblast cells, it will stimulate the RNAi channel and produce siRNA. The specific process is as follows:

[0024] 1. Experimental materials

[0025] Human trophoblast cells, wild-type HCMV, trophoblast culture medium containing 10% Gibco serum and 2% double antibody, trophoblast medium containing 2% serum, total RNA extraction kit (Gibco).

[0026] 2. Experimental process

[0027] (1) Pave a 24-well plate with trophoblast cells;

[0028] (2) When it grows to 70%-80% confluence, replace the trophoblast culture medium containing 10% Gibco serum and 2% double antibody with the trophoblast medium containing 2% serum (per hole culture medium The amount added is 0.5ml), and 5μl10 was added to each well 7 PFU / ml wild-type HCMV;

[0029] (3) After 48 hours of virus infection, collect samples and extract RNA with a total RNA extraction kit;

[0030] (4) Discard the supernatant, add 350 μl TRK lysate to the well, and put it on the shak...

Embodiment 2

[0042] In this example, a HFF cell model infected with HCMV labeled with green fluorescent protein was established for subsequent research on the inhibitory effect of ciprofloxacin on HCMV. The specific process is as follows:

[0043] 1. Experimental materials

[0044] Human foreskin fibroblasts (HFF), GFP-HCMV labeled with green fluorescent protein, DMEM medium containing 10% Gibco serum and 2% double antibody, DMEM medium containing 2% serum, fluorescence microscope.

[0045] 2. Experimental process

[0046] (1) Utilize the reverse genetics system to construct the GFP-HCMV virus whose genome can express green fluorescent protein;

[0047] (2) Pave a 24-well plate with HFF cells;

[0048] (3) When it grows to 70%-80% confluence, replace the DMEM medium containing 10% Gibco serum and 2% double antibody with the DMEM medium containing 2% serum (the amount of culture medium in each well is 0.5ml), add 5μl 10 per well 6 PFU / ml GFP-HCMV;

[0049] (4) After virus infection 4 d...

Embodiment 3

[0052] The present embodiment explores the inhibitory effect of ciprofloxacin (Cipro) on the viral level of HCMV, and the specific process is as follows:

[0053] 1. Experimental materials

[0054] Human foreskin fibroblasts (HFF), GFP-HCMV labeled with green fluorescent protein, DMEM medium containing 10% Gibco serum and 2% double antibody, DMEM medium containing 2% serum, PBS, fluorescence microscope.

[0055] 2. Experimental process

[0056] (1) spread HFF cells to 24-well plate;

[0057] (2) When it grows to 70%-80% confluence, replace the DMEM medium containing 10% Gibco serum and 2% double antibody with the DMEM medium containing 2% serum (the amount of culture medium in each well is 0.5ml), add 5μl 10 per well 7 PFU / ml GFP-HCMV;

[0058] (3) After virus infection 4h, abandon culture medium, wash twice with PBS, add the DMEM culture medium (the addition amount of every well culture medium is 0.5ml) freshly containing 2% serum, simultaneously in experimental group (be...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of ciprofloxacin in preparation of a human cytomegalovirus inhibitor. According to the invention, small RNA sequencing is carried out on cells infected with HCMV;after HCMV infection, siRNA can be generated to excite an RNAi antiviral pathway, and ciprofloxacin can enhance the RNAi pathway so that the virus level of HCMV can be effectively inhibited in cells,the virus replication level of HCMV can be inhibited, and diseases caused by HCMV infection can be prevented and / or treated.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of ciprofloxacin in the preparation of human cytomegalovirus inhibitors. Background technique [0002] Human cytomegalovirus (HCMV) is a DNA virus with the largest genome in the herpesvirus family and belongs to the β-herpesviruses, which can cause lifelong infection in humans. HCMV infection is very common in the population. In developed countries, the positive rate of HCMV antibody in adults is about 50%, while in our country it is as high as 60% to 80%. 10% to 15% of children are first infected with HCMV before the age of 5 years. Primary HCMV infection is generally asymptomatic in healthy hosts but can cause severe and sometimes fatal disease in immunocompromised individuals and neonates. HCMV is the main source of infection leading to congenital malformations in the world. Intrauterine infection of HCMV can cause obvious abnormal symptoms, i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61P31/20
CPCA61K31/496A61P31/20
Inventor 刘愈杰徐国东幸晓莹郑从义
Owner CANVEST WUHAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com